SCHEMBL9560238

SCHEMBL9560238

CCCCCCCCCCCCCCCC(=O)OCC(O)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.76
NR5A2 O00482 1/20 0.76
NR5A1 Q13285 1/20 0.76
MAPT P10636 2/20 0.73
LPAR6 P43657 1/20 0.62
LPAR1 Q92633 1/20 0.62
LPAR4 Q99677 1/20 0.62
LPAR5 Q9H1C0 1/20 0.62
LPAR2 Q9HBW0 1/20 0.62
LPAR3 Q9UBY5 1/20 0.62
ENPP2 Q13822 1/20 0.62
RECQL P46063 1/20 0.61
PLA2G1B P04054 1/20 0.60
PLA2G2A P14555 1/20 0.60
FABP3 P05413 1/20 0.58
PLA2G10 O15496 1/20 0.58
LMNA P02545 2/20 0.58
ESR1 P03372 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
CDC25A P30304 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30652127 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL29482586 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
Lysophosphatidylcholine SCHEMBL29651472 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL9015289 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
Lysophosphatidylcholine SCHEMBL19787878 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL11131776 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL31577414 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL31122371 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL19065066 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6
SCHEMBL30651187 1.00 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTLPAR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5255042-A None JP disclosed
JP-2169507-A None JP disclosed
CN-118924841-A Application of polygonatum odoratum extract in preparation of medicine for improving type 2 diabetes 浙江树人学院 2024-11-12 CN disclosed
US-20230226031-A1 Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof NAMMI THERAPEUTICS, INC. 2023-07-20 US disclosed
EP-3606534-B1 PHOSPHOLIPID DERIVATIVES AND THEIR USE AS MEDICAMENTS USTAV MOLEKULARNI GENETIKY AV CR V V I (CZ) 2021-05-12 EP disclosed
US-20180104364-A1 TEXAPHYRIN-PHOSPHOLIPID CONJUGATES AND METHODS OF PREPARING SAME UNIVERSITY HEALTH NETWORK (CA) 2018-04-19 US disclosed
JP-H05255042-A POWDERY MAKE-UP COSMETIC KANEBO LTD 1993-10-05 JP disclosed
JP-H02169507-A COSMETIC KANEBO LTD 1990-06-29 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226031-A1 Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof LCP2, LITAF, BAD SMN1; SMN2 1768/4885NR5A2 3931/4885NR5A1 4401/4885
US-20180104364-A1 TEXAPHYRIN-PHOSPHOLIPID CONJUGATES AND METHODS OF PREPARING SAME PLTP, PHOSPHO1, TEX13A SMN1; SMN2 2014/4885NR5A2 4189/4885NR5A1 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.